Researchers Use AI to Predict which COVID-19 Patients will Need a Ventilator to Breathe
The tool, developed through analysis of CT scans from nearly 900 COVID-19 patients diagnosed in 2020, was able to predict ventilator need with 84% accuracy.
The tool, developed through analysis of CT scans from nearly 900 COVID-19 patients diagnosed in 2020, was able to predict ventilator need with 84% accuracy.
Bittium Biosignals Ltd, a subsidiary of Bittium Corporation, and British ECG service provider, Technomed Limited, have today signed an agreement under which Bittium will purchase a 25 percent stake in Technomed's capital stock. The agreement will strengthen the partnership between the companies in the development of ECG technology that measure the electrical activity of the heart.
Accenture (NYSE: ACN) has named eight companies as finalists in the Accenture HealthTech Innovation Challenge, which brings together leading-edge startups with prominent health companies to tackle some of North America's greatest health challenges.
Attracting more than 2,600 startup applicants in the past five years, the Accenture HealthTech Innovation Challenge supports finding innovative approaches and solutions to help create better healthcare access, experiences and ultimately outcomes for all people.
The new Clinerion patent underpins any medical EHR database infrastructure that incorporates a hybrid model of cloud-and-local server node installations at individual hospitals, as well as any method for search of patient cohort care metrics across such a platform. This allows real-time search at each individual hospital across the entire network at once, returning aggregate metrics from the entire network.
Exscientia, a clinical-stage, artificial intelligence (AI)-driven pharmatech company, today announced that Bristol Myers Squibb has elected to in-license an immune-modulating drug candidate created by Exscientia. Exscientia has two active collaborations with Bristol Myers Squibb, which together focus on multiple therapeutic areas, including oncology and immunology.
Abbott (NYSE: ABT) has received U.S. Food and Drug Administration (FDA) clearance for its latest optical coherence tomography (OCT) imaging platform powered by the company's new Ultreon Software. This innovative imaging software combines OCT with artificial intelligence (AI) to provide physicians an enhanced, comprehensive view of coronary blood flow and blockages to assist physician decision-making and provide the best pathway for treatment.
Rapid integration of care services and secure data interchange has enabled Humber Teaching NHS Foundation Trust to embrace its EPR move to the cloud through Dedalus’ Healthcare Platform.
Humber Teaching NHS Foundation Trust, was the first NHS Trust to go live with the Dedalus Care Suite EPR and since moving to the cloud they have seen enhanced performance of the EPR.